School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan
Department of Disease Control, London School of Hygiene & Tropical Medicine Faculty of Infectious and Tropical Diseases, London, UK.
BMJ Open. 2023 Jun 20;13(6):e074896. doi: 10.1136/bmjopen-2023-074896.
Malaria infection and curable sexually transmitted infections and reproductive tract infections (STIs/RTIs) adversely impact pregnancy outcomes. In sub-Saharan Africa, the prevalence of malaria and curable STIs/RTIs is high and, where coinfection is common, combination interventions may be needed to improve pregnancy outcomes. The aim of this systematic review is to estimate the prevalence of malaria and curable STI/RTI coinfection during pregnancy, risk factors for coinfection and prevalence of associated adverse pregnancy outcomes.
We will use three electronic databases, PubMed, EMBASE and Malaria in Pregnancy Library to identify studies involving pregnant women attending routine antenatal care facilities in sub-Saharan Africa and reporting malaria and curable STI/RTI test results, published in any language since 2000. We will search databases in the second quarter of 2023 and repeat the search before completion of our analyses. The first two authors will screen titles and abstracts, selecting studies that meet inclusion criteria and qualify for full-text screening. If agreement on inclusion/exclusion cannot be reached, the last author will serve as arbiter. We will extract data from eligible publications for a study-level meta-analysis. We will contact research groups of included studies and request individual participant data for meta-analysis. The first two authors will conduct a quality appraisal of included studies using the GRADE system. The last author will adjudicate if the first two authors do not agree on any appraisals. We will conduct sensitivity analyses to test the robustness of effect estimates over time (by decade and half-decade periods), geography (East/Southern Africa vs West/Central Africa), gravidity (primigravidae, secundigravidae, multigravidae), treatment type and dosing frequency, and malaria transmission intensity.
We obtained ethics approval from the London School of Hygiene & Tropical Medicine (LSHTM Ethics Ref: 26167). Results of this study will be disseminated via peer-reviewed publication and presentation at scientific conferences.
CRD42021224294.
疟疾感染和可治愈的性传播感染和生殖系统感染(性传播感染/生殖系统感染)会对妊娠结局产生不利影响。在撒哈拉以南非洲,疟疾和可治愈的性传播感染/生殖系统感染的患病率很高,而且在合并感染较为常见的情况下,可能需要联合干预措施来改善妊娠结局。本系统综述的目的是估计妊娠期间疟疾和可治愈性传播感染/生殖系统感染合并感染的流行率、合并感染的危险因素以及相关不良妊娠结局的流行率。
我们将使用三个电子数据库,即 PubMed、EMBASE 和疟疾妊娠文库,以确定自 2000 年以来发表的涉及在撒哈拉以南非洲常规产前保健机构就诊的孕妇并报告疟疾和可治愈性传播感染/生殖系统感染检测结果的研究。我们将在 2023 年第二季度搜索数据库,并在完成分析之前重复搜索。前两位作者将筛选标题和摘要,选择符合纳入标准并符合全文筛选条件的研究。如果对纳入/排除标准无法达成一致意见,则由最后一位作者作为仲裁者。我们将从合格出版物中提取数据进行研究水平的荟萃分析。我们将联系纳入研究的研究小组,并要求提供个体参与者数据进行荟萃分析。前两位作者将使用 GRADE 系统对纳入研究进行质量评估。如果前两位作者对任何评估意见不一致,最后一位作者将进行裁决。我们将进行敏感性分析,以检验随着时间的推移(按十年和五年期)、地理(东/南部非洲与西/中部非洲)、孕次(初产妇、经产妇、多产妇)、治疗类型和给药频率以及疟疾传播强度的影响估计值的稳健性。
我们从伦敦卫生与热带医学院(LSHTM 伦理审查:26167)获得了伦理批准。本研究的结果将通过同行评审出版物和在科学会议上的报告进行传播。
PROSPERO 注册号:CRD42021224294。